Experience that can move a stalled or redirected asset again may become more valuable.
Capability · Asset Reconfiguration
The capability to reassess a stalled or redirected development asset, preserve what still matters and redesign the indication, development route or execution model so the asset can move again.
Repeating a successful project is different from deciding what to keep, what to discard and how to rebuild the route after the original path ends.
Why now
Hanmi is extending efpeglenatide through obesity and diabetes development while separately moving sonefpeglutide and HM17321 into global execution paths with Lilly and Genentech in 2026.
Core capability
Program Reassessment
Indication Reframing
Development-path Redesign
Recovery-to-Execution
Experience that strengthens it
Process Development
Medical / Clinical Context
Business Development
Manufacturing
Who to look at first
Process / Clinical Development or BD depth plus ownership of program reassessment, indication change or development recovery
What to check in the interview
Ask what assumption broke, which evidence remained useful, what was discarded and why the new route was chosen.
Build internally
Give strong development and BD talent ownership of reassessment and redesign programs, not only linear programs.
More existing assets are deliberately reworked into new indications or development paths
Roles explicitly own recovery after development or partner-path changes
Reassessed assets continue into clinical, manufacturing or commercialization milestones
Conditions that lower this view
Lower this view if future growth comes almost entirely from new discovery and reconfiguring existing, returned or redirected assets remains peripheral.
View evidence6
Roles & capabilities
ManufacturingObserved again
Process DevelopmentObserved again
Business DevelopmentObserved again
Business changes
Genentech licenses HM17321 for worldwide development outside Korea2026-08-24Source ↗
Lilly licenses sonefpeglutide across development, manufacturing and commercialization2026-06-01Source ↗
Efpeglenatide enters a new Phase 3 diabetes development path2026-05-18Source ↗
Talent pattern 2Early watch
The scarce skill may be making your output usable by the next function—not only excelling inside your own stage.
Capability · Boundary-Crossing Execution
The capability to turn the output of one development stage into a state the next organization can actually use across process, manufacturing, quality, business and partner boundaries.
Producing a strong result inside one function is different from making that result executable by the next function.
Why now
Hanmi is connecting internal pipelines to late-stage development and Pyeongtaek operations while its 2026 global agreements also connect development, manufacturing and commercialization to external partner execution.
Core capability
Development Handoff
Manufacturing Readiness
Partner-ready Package
Cross-functional Closure
Experience that strengthens it
Process Development
Manufacturing
Quality Assurance
Business Development
Who to look at first
Depth in Process Development / Manufacturing / QA / BD plus ownership of readiness and handoff across at least two functions
What to check in the interview
Ask what the next team needed, which gaps blocked the handoff and what the candidate personally closed.
Build internally
Give strong specialists shared ownership of downstream readiness and the next function’s handoff conditions.
Manufacturing changePyeongtaek Bio Plant starts AI-assisted QA document operations
Hanmi is applying Q-Agent first to QA work at the Pyeongtaek Bio Plant and plans to extend the operating model across quality and development functions.
Repeatedly observed: confirmed at several points in time · Observed: confirmed recently
Banseog analysisDevelopment assets are being reconfigured across internal execution and selective global amplification
CURRENT TALENT MARKET
Then see the talent market moving around it.
Career paths and talent movement linked to this company are still being observed.
Abbreviations on this page
CMC
Chemistry, manufacturing and controls
QA
Quality assurance
BD
Business development
Candidate market analysis for Hanmi Pharmaceutical
We analyse the candidate field, adjacent talent markets and hiring sequence for this shift. The detailed candidate field is shared only with the commissioning company.
![Banseog [ biohealth ]](/assets/brand/banseog-biohealth-on-dark.svg?v=20261015){kind=small}